The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.
The FDA has granted a to the BCMA-targeting Tri-specific T-cell Activating Construct, HPN217, for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who have previously received at least 4 lines of therapy.
Oliver Van Oekelen, MD, MSc, discusses findings from a retrospective study that evaluated treatment and efficacy outcomes in patients with relapsed or refractory multiple myeloma who experienced disease progression after BCMA-directed CAR T-cell therapy.
Ajai Chari, MD, discusses the safety and efficacy of talquetamab plus daratumumab in heavily pretreated patients with multiple myeloma, initial data from phase 1b TRIMM-2 trial, and the potential to move the combination into earlier lines of therapy.
The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed and/or refractory multiple myeloma following 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Expert hematologist-oncologists review the case of a 56-year-old man with multiple myeloma who received CAR T-cell therapy and share their approaches to treatment.
Katja Weisel, MD, reviews potential mechanisms of resistance to belantamab mafodotin in patients with multiple myeloma, and Sagar Lonial, MD, FACP, discusses potential treatment options for patients who progress on belantamab mafodotin.
Expert perspective on the INSURE study, which pooled data from several trials to observe the real-world effectiveness of IRd in the setting of relapsed/refractory multiple myeloma.
Thomas G. Martin, MD, discusses the patient population of the phase 2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.
The FDA has granted an orphan drug designation to the investigational anti-BCMA CAR T-cell therapy CT103A for use as a potential therapeutic option in patients relapsed/refractory multiple myeloma.
Joshua Richter, MD, and Sagar Lonial, MD, FACP, review key ongoing clinical trials with belantamab mafodotin in patients with multiple myeloma and the optimal position for belantamab mafodotin in the myeloma treatment landscape.
Katja Weisel, MD, shares recommended strategies for the prevention and management of potential ocular effects of belantamab mafodotin in multiple myeloma.
Thomas G. Martin, MD, discusses some of the exciting clinical trials open at UCSF Helen Diller Family Comprehensive Cancer Center in multiple myeloma, especially for those in the relapsed/refractory setting.
Dan Vogl, MD, MSCE, discusses the unique mechanism of action of modakafusp alfa and the updated results from an expansion cohort in patients with relapsed/refractory multiple myeloma.
Saad Z. Usmani, MD, MBA, FACP, shares key takeaways from presentations given during the meeting on the evolving paradigms of frontline, early relapsed, and late relapsed multiple myeloma, the current role of bispecific antibodies and CAR T-cell therapy, and emerging immunotherapies and also trials in progress in the space.
Ola Landgren, MD, PhD, and Joshua Richter, MD, review belantamab mafodotin–based combination regimens currently being evaluated in relapsed/refractory multiple myeloma, as well as the newly diagnosed setting, as presented at the recent ASH 2021 meeting.
Sagar Lonial, MD, reviews key takeaways from the DREAMM-2 trial, and Katja Weisel, MD, comments on the potential use of belantamab mafodotin in the early relapse setting for multiple myeloma.
Laura Finn, MD, provides a deep dive into pivotal data with combinations and novel agents that have changed the paradigm for patients with newly diagnosed, early relapsed, and late relapsed multiple myeloma.
Douglas W. Sborov, MD, MS, discusses key data and therapeutic developments that have reshaped the treatment of patients with newly diagnosed and relapsed/refractory multiple myeloma.